Hsu Wen-Yu, Lee Chien-I, Chiu Nan-Ying, Kahn David A
Changhua Christian Hospital, Changhua, Taiwan.
J Psychiatr Pract. 2009 May;15(3):221-6. doi: 10.1097/01.pra.0000351883.75754.45.
Clozapine is the first choice antipsychotic medication for treatment-refractory schizophrenia; however, there are some disadvantages in using clozapine. A few reports have appeared concerning switching from clozapine to other antipsychotics for treatment-refractory schizophrenia. This report describes the case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20 mg/day because of changes in consciousness. After the switch to aripiprazole, the patient's psychotic condition improved. As expected, we identified few successful cases of switches from clozapine in our search of the literature. Although controlled clinical trial data support use of clozapine in treatment-refractory schizophrenia, some patients cannot tolerate this agent or it may increase the risk of physical problems for some patients. In such situations, clinicians may want to consider prescribing a different antipsychotic or adding another antipsychotic and decreasing the dosage of clozapine.
氯氮平是治疗难治性精神分裂症的首选抗精神病药物;然而,使用氯氮平存在一些缺点。已有一些关于难治性精神分裂症患者从氯氮平换用其他抗精神病药物的报道。本报告描述了一名58岁难治性精神分裂症女性患者的病例,该患者因意识改变成功地从每日300毫克氯氮平换用为每日20毫克阿立哌唑。换用阿立哌唑后,患者的精神病症状得到改善。正如预期的那样,我们在文献检索中发现很少有从氯氮平成功换药的病例。尽管对照临床试验数据支持氯氮平用于治疗难治性精神分裂症,但一些患者无法耐受该药物,或者该药物可能会增加一些患者出现身体问题的风险。在这种情况下,临床医生可能会考虑开具不同的抗精神病药物,或加用另一种抗精神病药物并减少氯氮平的剂量。